A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

NCT01510561 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped no subjects enrolled

Conditions

Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions

DRUG: 90Y-hPAM4
DRUG: 90Y-hPAM4
DRUG: 90Y-hPAM4 + gemcitabine

Sponsor

Gilead Sciences